Internal Medicine, Gastroenterology · Houston, TX
NPI
1215920723
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
444 Fm 1959 Rd, Ste A
Houston, TX, 77034
Phone (281) 481-9400
Groups this clinician bills Medicare through
Medicare paid, 2024
$187K
4,238 services
Medicare patients, 2024
580
Average age 74
Drug cost, 2024
$576K
2,539 prescriptions
Company payments, 2025
$850
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Suresh K Rajendran was code 99213 (office e&m - established), 246 times for 204 patients. In total Suresh K Rajendran billed 4,238 services in 30 codes, and Medicare paid $187K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 246 | 204 | $65.75 | $16K |
| 99214 Office E&M - Established | Office | 201 | 174 | $87.69 | $18K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 169 | 44 | $49.95 | $8,441 |
| 45385 Colonoscopy - Lesion Removal | Facility | 154 | 153 | $208.95 | $32K |
| 43239 Upper GI Endoscopy | Facility | 136 | 134 | $74.53 | $10K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 121 | 39 | $38.21 | $4,623 |
| 99204 Office E&M - New | Office | 99 | 99 | $105.89 | $10K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 70 | 70 | $183.19 | $13K |
| 99203 Office E&M - New | Office | 61 | 61 | $70.17 | $4,281 |
| 99212 Office E&M - Established | Office | 55 | 55 | $42.28 | $2,325 |
| 99202 Office E&M - New | Office | 47 | 47 | $45.80 | $2,153 |
| 45380 Lower GI Endoscopy - Other | Facility | 45 | 45 | $114.24 | $5,141 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 24 | 24 | $183.36 | $4,401 |
| 43249 Upper GI Endoscopy | Facility | 24 | 23 | $91.01 | $2,184 |
| 45378 Lower GI Endoscopy - Other | Facility | 17 | 17 | $138.91 | $2,361 |
By year: 2022 $174K for 3,167 services; 2023 $209K for 6,287 services; 2024 $187K for 4,238 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 251 | 120 | $27.43 | $6,885 |
| 88312 Surgical Pathology Examination | 70 | 44 | $67.75 | $4,743 |
| 88313 Surgical Pathology Examination | 68 | 44 | $53.63 | $3,647 |
Medicare prescription drug claims, 2024
In 2024, the drug Suresh K Rajendran prescribed most often to Medicare patients was Pantoprazole Sodium, with 732 prescriptions and refills. In total Suresh K Rajendran wrote 2,539 Medicare prescriptions that cost $576K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 732 | 1,629 | 262 | $7,462 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 419 | 419 | 411 | $25K |
| Famotidine Generic | 268 | 497 | 101 | $2,992 |
| Sucralfate Generic | 119 | 139 | 53 | $3,206 |
| Colestipol Hcl Generic | 96 | 142 | 34 | $8,154 |
| Omeprazole Generic | 80 | 202 | 37 | $1,107 |
| Mesalamine Er Mesalamine | 63 | 79 | Under 11 | $31K |
| Linzess Linaclotide | 60 | 106 | 21 | $54K |
| Lansoprazole Generic | 60 | 118 | 18 | $3,400 |
| Mesalamine Generic | 59 | 93 | 15 | $21K |
| Esomeprazole Magnesium Generic | 58 | 122 | 24 | $1,605 |
| Ursodiol Generic | 51 | 79 | Under 11 | $6,619 |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 46 | 46 | 46 | $840 |
| Dicyclomine Hcl Generic | 43 | 57 | 22 | $887 |
| Entecavir Generic | 30 | 52 | Under 11 | $5,162 |
Brand drugs: - claims; generic drugs: 2,111 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Suresh K Rajendran $850 ($850 in general payments such as food, travel and fees) from 8 companies. The largest payer was Abbvie Inc. with $407.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 22 | $407 |
| Madrigal Pharmaceuticals MDGL | 5 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $149 |
| Gilead Sciences, Inc. GILD | 2 | $40.63 |
| Novo Nordisk Inc NVO | 2 | $40.57 |
| Janssen Biotech, Inc. JNJ | 1 | $21.63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 1 | $19.06 |
| Pfizer Inc. PFE | 1 | $18.49 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.